Among them, low dose cyclophosphamide induces anti-tumor T-cell response (63), modulates tumor microenvironment through TGF-β pathway (64), and induces ferroptosis through Heme Oxygenase-1 (65), which plays an important immunomodulatory role in cancer immunotherapy (66). Here, TGFB1 is linked to neoplasm.